Harnessing the restorative potential of novel CNS therapeutics through remyelination and anti-neuroinflammation
Learn MoreDeveloping therapeutics to address the unmet need and societal burdens posed by neurodegenerative and demyelinating disorders.
Introducing Myrobalan Therapeutics, where the collective expertise of our scientific co-founders propels the development of transformative therapies for CNS diseases. With our scientific foundations driven by our co-founders, Harvard Professor Zhigang He, MIT Professor Guoping Feng, and our industry seasoned CEO, Dr. Jing Wang, we pioneer innovative treatments targeting demyelination and neuroinflammation. Together, with a comprehensive in-house R&D team, we strive to redefine brain health for patients worldwide.
At Myrobalan, we are poised to pioneer first-in-class and best-in-class small molecule therapies addressing a wide range of CNS diseases with significant unmet needs. Our strategy emphasizes remyelination and anti-neuroinflammation, targeting conditions such as multiple sclerosis, Alzheimer's disease, ALS, Parkinson's, and various demyelinating and degenerative disorders. Join us as we lead the charge towards transformative treatments in neurological disease.
Myrobalan is a plant held by the Medicine Buddha whenever he is pictured. According to Tibetan Buddhism tradition, Myrobalan is regarded as the only herb capable of healing illnesses that have their root cause in conflicting emotions.
